For patents, the Singapore Patents Act, section 66, contains the legislative provisions defining the exhaustion defence. The general defence is provided in section 66(2); in respect of pharmaceuticals it is subject to the limitations provided in subsections (3) to (5A).
The general defence is provided in section 66(2), which states:
"An act which, apart from this subsection, would constitute an infringement of a patent for an invention shall not be so if -…
… (g) subject to subsections (3) and (5A), it consists of the import, use or disposal of, or the offer to dispose of, any patented product or any product obtained by means of a patented process or to which a patented process has been applied, which is produced by or with the consent (conditional or otherwise) of the proprietor of the patent or any person licensed by him, and for this purpose "patent" includes a patent granted in any country outside Singapore in respect of the same or substantially the same invention as that for which a patent is granted under this Act and "patented product", "patented process" and "licensed" shall be construed accordingly;"
The defence applies to dealings in respect of, and use of, an imported patented product or a product obtained by means of a patented process. However, the defence does not apply to the use of a patented process in Singapore. The defence applies even if the proprietor of the patent in Singapore is different from the proprietor of the patent in the country of manufacture, for example because the original owner of the patents in both Singapore and the country of manufacture subsequently sold its rights in the latter patent.
For the purpose of determining whether the product in question was produced by or with the consent of the owner of the patent, any condition imposed by the patentee restricting the resale of the product outside the territory of manufacture/first sale must be disregarded. Contractual terms and label disclaimers do not operate to override operation of the exhaustion defence in patent law in Singapore.
Pursuant to section 66(3), the general exhaustion defence does not apply (broadly speaking) to the importation of pharmaceuticals, in particular those: not previously sold or distributed in Singapore by or with the consent of the proprietor of the patent or their licensee; and the import of which would amount to breach of contract between the proprietor of the patent and a licensed distributor outside Singapore, and of which the importer would have knowledge.
Pursuant to section 66(5A), the general exhaustion defence does not apply to the import or sale of, or the offer to sell, any relevant health product produced for export to a country which is an eligible importing member of the World Trade Organisation (i.e. the least developed countries).
Additionally, a specific defence is also provided in section 66(2)(i) for the importation and disposal of a patented pharmaceutical for use by a specific patient in Singapore, in qualifying circumstances.